Navigation Links
MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
Date:12/19/2011

DALLAS, December 19, 2011 /PRNewswire/ --

The "Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, and Japan.

Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020).
http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html
Early buyers will receive 10% customization on reports.

Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body from infections caused by bacteria. Acute myeloid leukemia is divided into childhood acute myeloid leukemia and adult acute myeloid leukemia.

Acute myeloid leukemia has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15-70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

The acute myeloid leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html ] in G8 countries was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD regimen in 2010. AVD regimen accounted for the largest share; i.e. 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cytarabine drug and Quizartinib molecule, with sales amounting to $698 million, $285 million, and $234 million respectively.

According to WHO, acute myeloid leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of acute myeloid leukemia. Global incidence of acute myeloid leukemia was 49,539 in 2008 with the developing countries. Total 62,226 new cases were recorded in 2010 with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.

The U.S. dominates the leukemia drug market in North America with a 90.19% share; whereas Germany dominates the market of Europe with 35.04% share.

The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://twitter.com/marketsmarkets



'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
3. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
8. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 2017 , ... A research team led by Mai Lam, ... Video Journal, the world’s first peer-reviewed scientific video journal. The article demonstrates a ... disease (CAD). Lam is an assistant professor at the Department of Biomedical Engineering ...
(Date:3/24/2017)... Ga. , March 24, 2017 MiMedx ... biopharmaceutical company utilizing human placental tissue allografts and patent-protected ... for multiple sectors of healthcare, announced today  that it ... New York , NY.  Parker H. "Pete" ... Chief Financial Officer, Christopher M. Cashman , EVP ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
(Date:3/23/2017)... ... ... proud to announce it has become the premiere team-building cooking event company in San Diego. ... such as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip ... its new team building format, a way for teams to not only interact with one ...
Breaking Biology Technology:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
Breaking Biology News(10 mins):